We use essential cookies to make this website work and to help improve it for you.
Change website language
Cymraeg – Newid yr iaith ir Gymraeg
English
Home
This WEDINOS report highlights emerging concerns in the UK’s illicit drug market, particularly the prevalence of Synthetic Cannabinoid Receptor Agonists (SCRAs), synthetic opioids, and misrepresented MDMA samples.
Category: Annual reports, Drug testing (WEDINOS), Evidence and research
This research, focusing on mortality, forms part of a larger study examining the type and timing of healthcare service contact prior to the start of problematic or enduring substance misuse […]
Category: Data and analysis
Annual statistical report on drug related mortality in Wales using national health statistics and the Harm Reduction Database Wales.
WEDINOS analysis again highlights concerns of substance substitution within the UK drug market. Over the past year, Bromazolam was the most commonly identified benzodiazepine, and most often purchased with the […]
Category: Annual reports, Data and analysis, Drug testing (WEDINOS)
Epidemiology Pertussis incidence typically has a cyclical pattern with peaks in cases every three to four years. The peak prior to 2012 in England and Wales was in 2008, with […]
Category: Evidence and research
Summary This report outlines the background to, and action required for, the implementation of dried blood spot (DBS) testing of substance misuse service clients across Wales for evidence of exposure […]
A report into the exploration of factors influencing the application of behavioural science within public health practice across Wales. Behaviours play a key role in improving health and wellbeing.Identifying and […]
This report is a detailed summary of information on work undertaken by the Welsh Breast Screening Programme for the year April 2017 to the end of March 2018. The aim […]
This report is a detailed summary of information on work undertaken by the Breast Screening Programme in Wales for the year April 2020 to the end of March 2021. The […]
Background The pneumococcal polysaccharide vaccination (PPV) is currently offered to those aged 65 years and over and people aged two to 64 years in select clinical risk groups. PPV protects […]
